Tech Company Financing Transactions

LifeMine Therapeutics Funding Round

LifeMine Therapeutics, based in Cambridge, secured $55 million from WuXi Healthcare Ventures, Alexandria Venture Investments and Arch Venture Partners.

Transaction Overview

Company Name
LifeMine Therapeutics
Announced On
9/19/2017
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series A
Investors

WuXi Healthcare Ventures (Lead Investor) (Edward Hu)

Alexandria Venture Investments

Arch Venture Partners

Blue Pool Capital

Boyu Capital (Yanling Cao)

Foresite Capital (James Tananbaum)

GV (Krishna Yeshwant)

Merck Global Health Innovation Fund

Proceeds Purpose
Concurrent with the funding, the company announced the launch of its public operations.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
30 Acorn Park Dr.
Cambridge, MA 02140
USA
Phone
(617) 665-5000
Website
www.lifeminetx.com
Email Address
[email protected]
Overview
LifeMine is the first company to massively scale the genomic discovery of powerful new drug modalities from eukaryotic microbes. Our integrated, genomically-enabled drug discovery engine is poised to deliver a pipeline of medicines that will conquer previously unconquerable human diseases.
Profile
LifeMine Therapeutics LinkedIn Company Profile
Social Media
LifeMine Therapeutics Company Twitter Account
Company News
LifeMine Therapeutics News
Facebook
LifeMine Therapeutics on Facebook
YouTube
LifeMine Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Richard Klausner
  Richard Klausner LinkedIn Profile  Richard Klausner Twitter Account  Richard Klausner News  Richard Klausner on Facebook
Chief Executive Officer
Gregory Verdine
  Gregory Verdine LinkedIn Profile  Gregory Verdine Twitter Account  Gregory Verdine News  Gregory Verdine on Facebook
Chief Operating Officer
WeiQing Zhou
  WeiQing Zhou LinkedIn Profile  WeiQing Zhou Twitter Account  WeiQing Zhou News  WeiQing Zhou on Facebook
Vice President
Paola Castaldi
  Paola Castaldi LinkedIn Profile  Paola Castaldi Twitter Account  Paola Castaldi News  Paola Castaldi on Facebook
Vice President
Jared Cumming
  Jared Cumming LinkedIn Profile  Jared Cumming Twitter Account  Jared Cumming News  Jared Cumming on Facebook
Vice President
Thomas Ramseier
  Thomas Ramseier LinkedIn Profile  Thomas Ramseier Twitter Account  Thomas Ramseier News  Thomas Ramseier on Facebook
Vice President
Dawn Thompson
  Dawn Thompson LinkedIn Profile  Dawn Thompson Twitter Account  Dawn Thompson News  Dawn Thompson on Facebook
VP - Bus. Development
Iain McFadyen
  Iain McFadyen LinkedIn Profile  Iain McFadyen Twitter Account  Iain McFadyen News  Iain McFadyen on Facebook
VP - Bus. Development
Susanne Saalau
  Susanne Saalau LinkedIn Profile  Susanne Saalau Twitter Account  Susanne Saalau News  Susanne Saalau on Facebook
VP - Finance
Karen Guarco
  Karen Guarco LinkedIn Profile  Karen Guarco Twitter Account  Karen Guarco News  Karen Guarco on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/19/2017: Cofactor Genomics venture capital transaction
Next: 9/19/2017: Matroid venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.